Tandem Diabetes Care (TNDM) Short term Debt (2024 - 2025)

Tandem Diabetes Care (TNDM) reported Short term Debt of $40.7 million for Q1 2025, little changed quarter-over-quarter from $40.7 million in Q4 2024.

Tandem Diabetes Care (TNDM) Short term Debt (2024 - 2025) Analysis & Trends

Tandem Diabetes Care has reported Short term Debt for 2 years, with the latest figure at $40.7 million in Q1 2025.

For the quarter ending Q1 2025, Short term Debt changed N/A year-over-year to $40.7 million; the trailing twelve-month figure through Mar 2025 stood at $40.7 million (changed N/A YoY), and the FY2024 full-year result was $40.7 million, changed N/A from the prior year.
Short term Debt for Q1 2025 stood at $40.7 million, roughly flat from $40.7 million in the prior quarter.
The five-year high for Short term Debt was $40.7 million in Q1 2025, with the low at $40.5 million in Q2 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Abbott Laboratories	154.42 Bn	147.76 Bn	6.27 Bn
2	Stryker	118.12 Bn	115.25 Bn	3.81 Bn
3	Medtronic	101.72 Bn	93.55 Bn	5.76 Bn
4	Boston Scientific	67.19 Bn	65.98 Bn	3.61 Bn
5	Edwards Lifesciences	50.69 Bn	47.02 Bn	1.29 Bn
6	Koninklijke Philips	29.38 Bn	26.07 Bn	2.07 Bn
7	Dexcom	28.09 Bn	26.97 Bn	750.30 Mn
8	GE HealthCare Technologies	28.08 Bn	26.02 Bn	1.98 Bn
9	Steris	19.80 Bn	19.37 Bn	697.10 Mn
10	Tandem Diabetes Care	1.04 Bn	474.17 Mn	136.79 Mn

Download Data